Difference between revisions of "Team:British Columbia/Human Practices"
m |
m |
||
| Line 30: | Line 30: | ||
.sidebar-nav{ | .sidebar-nav{ | ||
text-align: left; | text-align: left; | ||
| − | |||
} | } | ||
} | } | ||
| Line 89: | Line 88: | ||
<div class="content-wrap"> | <div class="content-wrap"> | ||
<div class="row"> | <div class="row"> | ||
| − | <nav class="col-sm-3" id="side-menu"> | + | <nav class="col-sm-3" id="side-menu" style="margin-right: 25px"> |
<ul class="nav sidebar-nav nav-pills nav-stacked"> | <ul class="nav sidebar-nav nav-pills nav-stacked"> | ||
<li class="active"><a href="#who-we-are">Who We Are</a></li> | <li class="active"><a href="#who-we-are">Who We Are</a></li> | ||
Revision as of 22:37, 16 October 2016
Human Practices
S-layer Engineering
The mesophilic organism Lysinibacillus sphaericus CCM 2177 produces the surface (S)-layer protein SbpA, which after secretion completely covers the cell surface with a crystalline array exhibiting square lattice symmetry. Because of its excellent in vitro recrystallization properties on solid supports, SbpA represents a suitable candidate for genetically engineering to create a versatile self-assembly system for the development of a molecular construction kit for nanobiotechnological applications. The first goal of this study was to investigate the surface location of 3 different C-terminal amino acid positions within the S-layer lattice formed by SbpA. Therefore, three derivatives of SbpA were constructed, in
